Feb 20 (Reuters) - Immunic Inc IMUX.O:
IMMUNIC'S ORAL IMU-856 DEMONSTRATED DOSE-DEPENDENT INCREASE OF GLP-1 IN CELIAC DISEASE PATIENTS AND CORRESPONDING EFFECTS IN PRECLINICAL TESTING
IMMUNIC INC: DOSE-DEPENDENT REDUCTION OF BODY WEIGHT GAIN AND FOOD CONSUMPTION OBSERVED IN PRECLINICAL STUDY
IMMUNIC: DOSE-DEPENDENT INCREASE OF ENDOGENOUS GLP-1 LEVELS OBSERVED IN POST HOC ANALYSIS OF PATIENTS FROM PHASE 1B CLINICAL TRIAL IN CELIAC DISEASE
Source text: ID:nPn12yQH3a
Further company coverage: IMUX.O
((Reuters.Briefs@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。